SpringWorks Therapeutic’s Acquisition Of SpringWorks’ Inhibitor Program

Goodwin Procter LLP advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its asset purchase and exclusive license agreement under which Jazz Pharmaceuticals...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here